سعر ريجيوفوز 800مجم 30قرص 2025
Reguphose 800 mg- المادة الفعالة: Sevelamer
- Eva Pharma
- عن طريق الفم
الفئة: رابط للفوسفات
معلومات الدواء
التفاصيل الكاملةعن الدواءAbout the medicine
Sevelamer 800 mg film-coated tablets (phosphate binder for hyperphosphataemia in chronic kidney disease), 30 tablets in 3 strips.
Sevelamer 800 mg film-coated tablets (phosphate binder for hyperphosphataemia in chronic kidney disease), 30 tablets in 3 strips.
دواعي الاستعمالUses
- Control of serum phosphorus in adults and children 6 years and older with chronic kidney disease on dialysis.الفئة: Adults and children >=6 years on dialysisDailyMed (U.S. National Library of Medicine)
- Control of serum phosphorus in adults and children 6 years and older with chronic kidney disease on dialysis.Population: Adults and children >=6 years on dialysisDailyMed (U.S. National Library of Medicine)
الآثار الجانبيةSide effects
- With sevelamer hydrochloride (>5%): vomiting, nausea, diarrhoea, dyspepsia, abdominal pain, flatulence and constipation.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)
- With sevelamer hydrochloride (>5%): vomiting, nausea, diarrhoea, dyspepsia, abdominal pain, flatulence and constipation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
موانع الاستعمالContraindications
- Bowel obstruction.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)
- Known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride or any excipient.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)
- Bowel obstruction.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
- Known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride or any excipient.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
تحذيرات واحتياطاتWarnings & precautions
- Dysphagia and oesophageal tablet retention have been reported with tablets; bowel obstruction, GI bleeding, ulceration, necrosis and perforation have also been reported. Re-evaluate in severe GI symptoms.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)
- May reduce vitamins D, E, K (clotting factors) and folic acid levels; consider supplementation.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)
- Dysphagia and oesophageal tablet retention have been reported with tablets; bowel obstruction, GI bleeding, ulceration, necrosis and perforation have also been reported. Re-evaluate in severe GI symptoms.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
- May reduce vitamins D, E, K (clotting factors) and folic acid levels; consider supplementation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
التداخلات الدوائيةDrug interactions
- Oral drugs with narrow therapeutic index (e.g., cyclosporine, tacrolimus, levothyroxine)May reduce bioavailability; separate administration times and monitor clinical response or blood levels.DailyMed (U.S. National Library of Medicine)
- Oral drugs with narrow therapeutic index (e.g., cyclosporine, tacrolimus, levothyroxine)May reduce bioavailability; separate administration times and monitor clinical response or blood levels.DailyMed (U.S. National Library of Medicine)
الحمل والرضاعةPregnancy & breastfeeding
- Not absorbed systemically, so maternal use is not expected to result in fetal exposure; may lower fat-soluble vitamin and folic acid levels, consider supplementation.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)
- Not absorbed systemically; breastfeeding is not expected to expose the infant.نشرة دولية لتركيبة مكافئة · DailyMed (U.S. National Library of Medicine)
- Not absorbed systemically, so maternal use is not expected to result in fetal exposure; may lower fat-soluble vitamin and folic acid levels, consider supplementation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
- Not absorbed systemically; breastfeeding is not expected to expose the infant.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
كيف يعمل الدواءHow it works
- Non-absorbed cross-linked amine polymer that binds dietary phosphate in the gut and lowers serum phosphorus (US Renvela label 12.1).
- Sevelamer: Non-absorbed cross-linked amine polymer that binds dietary phosphate in the gut and lowers serum phosphorus (US Renvela label 12.1).
المثائل (3)
كل المثائل والبدائلنفس المادة الفعالة والتركيز. اسأل الصيدلي قبل الاستبدال.
| الدواء | السعر | الفرق عن الأصلي |
|---|---|---|
| سيفيلام 800مجم 15 قرصSevelamGlobal Napi Pharmaceuticals · أقراص مغلفة · 800 mgالأرخص | السعر79.5ج.م5.3ج.م للوحدة | الفرق عن الأصليأرخص 220.5ج.م (73.5%) |
| رينافيلامير 800مجم 30 قرصRenavelamer 800mg 30 f.c.tabsBiocapital Pharma · 800 mg | السعر300ج.م10ج.م للوحدة | الفرق عن الأصلينفس السعر |
| ريناجيل 800مجم 180 قرصRenagel 800 mg 180 f.c.tabsSanofi · 800 mg | السعر2,808ج.م15.6ج.م للوحدة | الفرق عن الأصليأغلى 2,508ج.م (836%) |
تاريخ السعر
تغيّر السعر الرسمي: من 120 إلى 300 ج.م، 2 أسعار مسجلة
| التاريخ | السعر (ج.م) |
|---|---|
| سعر سابق بدون تاريخ | 120 |
| 300 |
| التاريخ | من | إلى | التغيير |
|---|---|---|---|
| 120ج.م | 300ج.م | زيادة 150% |
المعرّفات
- الباركود
- 6223002454716
أدوية ذات صلة
منتجات أخرى من EVA Pharma
المصادر
- السعر: قوائم أسعار الأدوية المنشورة في مصر.
- DailyMed (U.S. National Library of Medicine)
تعليقات
لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.
أضف تعليقًا